Ensysce Biosciences, Inc. (ENSC) Stock Price & Analysis
Ensysce Biosciences, Inc. (ENSC) closed at USD 0.47 on Friday, October 23, 2026, down 7.93% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 0.51; the Oct 23, 2026 session ranged USD 0.47–0.52 on volume of 237,132 shares. Market capitalization is $9.15M, with a 52-week range of USD 0.23–2.26 (NCM). Source: Nexqual, retrieved October 24, 2026 at 13:34 UTC.
Also available as compact Markdown for AI agents: nexqual.com/ENSC.md
Key facts (ENSC)
- Last four reported quarters (through Jun 30, 2026): revenue $4.5M, net income -$12.6M (-280.5% margin) (SEC filings).
- Insider open-market purchases, last ~7 months: 1 Form 4 filing, $444K; 0 by opportunistic insiders, 0 by routine insiders.
- Analysts: Buy (mean 2.00 on a 1–5 scale) (1 analysts), mean target USD 5.13 (range 2–8.25).
- Total return with dividends: 1Y -78.9% vs S&P 500 +13.4%; 5Y -100.0% vs S&P 500 +76.9%.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (ENSC)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $3.5M | $2.5M | $2.2M | $5.2M | $5.1M | $4.5M |
| Operating income | -$19.9M | -$24.2M | -$10.7M | -$6.7M | -$10.2M | -$12.7M |
| Net income | -$29.1M | -$24.2M | -$10.6M | -$8.0M | -$10.2M | -$12.6M |
| EPS (diluted) | -$5328.00 | -$2091.30 | -$70.40 | -$11.45 | -$3.98 | — |
| Free cash flow | — | — | — | — | -$7.9M | — |
| Operating margin | -562.7% | -959.9% | -480.5% | -129.2% | -202.1% | -281.3% |
| Net margin | -825.4% | -959.3% | -476.4% | -153.3% | -200.8% | -280.5% |
| Revenue growth | -10.2% | -28.5% | -11.6% | +133.6% | -2.8% | — |
| Cash + short-term investments | $12.3M | $3.1M | $1.1M | $3.5M | $4.3M | — |
| Total debt | $4.4M | $140K | — | — | — | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (ENSC)
P/S 2.0x · Earnings yield -137.90%
Insider purchases (SEC Form 4, open-market, last ~7 months) (ENSC)
1 purchase, $444K. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-04-23…2026-08-07 | Gower Bob G | Director | 908,614 | $444K | 0.49 | Too little history (no open-market trades in 2024 or 2025) |
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (ENSC)
Consensus Buy (mean 2.00 on a 1–5 scale), 1 analysts; mean target USD 5.13 (low 2, high 8.25).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-20 | Cantor Fitzgerald | Initiated | Overweight | $2 |
Total return (dividends reinvested) (ENSC)
| 1Y (from 2025-10-24) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | -78.9% | -100.0% |
| S&P 500 (SPY) | +13.4% | +76.9% |
| Per year | -79.0% | -85.7% |
| Volatility (annualized) | 126.6% | 139.8% |
| Max drawdown | -88.7% (Oct 2025→Jun 2026) | -100.0% (Dec 2021→Jun 2026) |
ENSC suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | Purisys | “We have entered into an agreement with Purisys LLC ("Purisys")” |
Quoted from the company's 10-K filed Mar 30, 2026.
ENSC analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.12 | $0.09 | -233.3% | $1.2M | 2 |
| Next quarter (ends Dec 2026) | $-0.10 | $-0.60 | -84.2% | $1.2M | 2 |
| Current fiscal year (ends Dec 2026) | $-0.60 | $-1.53 | -60.8% | $4.5M | 2 |
| Next fiscal year (ends Dec 2027) | $-0.05 | $0.00 | — | $3.0M | 1 |
Key Statistics (as of October 24, 2026 at 13:34 UTC)
| Price | USD 0.47 |
|---|---|
| Change | ▼ 7.93% (down) |
| Previous Close | USD 0.51 |
| Open | USD 0.52 |
| Day Range | USD 0.47 – 0.52 |
| 52-Week Range | USD 0.23 – 2.26 |
| Volume | 237,132 shares |
| Market Cap | $9.15M |
| Exchange | NCM |
Technical Analysis (ENSC)
Nexqual's technical model rates ENSC "NEUTRAL" based on 3 bullish and 2 bearish signals across 127 daily candles, as of October 24, 2026 at 13:34 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 46.63 (neutral) |
| vs SMA50 | Above (USD 0.45) |
| MACD | 0.02 (positive) |
Analyst Ratings (ENSC)
Wall Street analysts rate ENSC "Buy" based on 1 analysts, with a mean price target of USD 5.13 (range USD 2–8.25), per Nexqual as of October 24, 2026 at 13:34 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 5.13 |
| High Target | USD 8.25 |
| Low Target | USD 2 |
| Buy / Hold / Sell | 1 / 0 / 0 |
Earnings (ENSC)
| Revenue Estimate | $1.20M |
|---|
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.2 vs est -0.5 ▲ beat |
| 2026-03-31 | USD -0.52 vs est -0.73 ▲ beat |
| 2025-12-31 | USD -0.75 vs est -1.26 ▲ beat |
| 2025-09-30 | USD -1.29 vs est -0.93 ▼ miss |
Source: Nexqual, October 24, 2026 at 13:34 UTC.
Financials & Fundamentals (ENSC)
| Total Revenue | $4.50M |
|---|---|
| Revenue Growth (latest quarter, YoY) | -15.10% |
| Gross Margin | -175.21% |
| Operating Margin | -221.28% |
| Profit Margin | -280.48% |
| ROE | -1295.09% |
| Current Ratio | 0.7 |
| Total Cash | $676,704 |
| Total Debt | $196,842 |
| Free Cash Flow (fiscal year ended Dec 2025, SEC 10-K) | -$7.93M (-156.5% of revenue) |
Source: Nexqual, October 24, 2026 at 13:34 UTC.
Financial Health Score (ENSC)
Nexqual rates Ensysce Biosciences, Inc.'s overall financial health "Weak" across five dimensions, as of October 24, 2026 at 13:34 UTC.
| Growth | Weak — Revenue -3% YoY (annual), declining |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $677K cash, no debt |
| Cash Flow | Weak — FCF negative: -$8M (FY ended Dec 2025, 10-K), burning cash |
| Efficiency | Critical — ROE -1295%, ROA -185.5% |
Ownership (ENSC)
| Insider Ownership | +4.72% |
|---|---|
| Institutional Ownership | +4.65% |
| Shares Outstanding | 19.46M |
| Float | 18.54M |
| Short % of Float | +5.56% |
Source: Nexqual, October 24, 2026 at 13:34 UTC.
Leadership (ENSC)
Ensysce Biosciences, Inc. is led by D. Lynn Kirkpatrick, CEO & Director, per Nexqual as of October 24, 2026 at 13:34 UTC.
| CEO & Director | D. Lynn Kirkpatrick |
|---|---|
| CFO, Secretary & Treasurer | David C. Humphrey |
| President & Director | James Morrison |
| Chairman of Clinical Advisory Board & Chief Medical Officer | William K. Schmidt |
Major Backers & Investors (ENSC)
Notable institutional backers of Ensysce Biosciences, Inc. include Jane Street Group, LLC, Adage Capital Partners GP L.L.C., Virtu Financial LLC, according to Nexqual as of October 24, 2026 at 13:34 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Jane Street Group, LLC | 1.07% |
| Adage Capital Partners GP L.L.C. | 0.77% |
| Virtu Financial LLC | 0.49% |
| Perceptive Advisors Llc | 0.45% |
| Citadel | 0.44% |
| Xtx Topco Ltd | 0.4% |
| Fidelity | 0.31% |
| HRT Financial LP | 0.28% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Geode Capital | 0.32% |
Source: Nexqual, October 24, 2026 at 13:34 UTC.
From Ensysce Biosciences, Inc.'s Latest SEC 10-K Filing (filed 2026-03-30)
Key Strengths & Strategy (as disclosed to the SEC)
- Prescription opioid abuse presents major burdens to society, resulting in significant costs, illnesses, and deaths, many of which we believe could be prevented through the use of our proprietary technologies.
- We also rely on trademarks, trade secrets, know-how, continuing technological innovation, and potential in-licensing opportunities to develop and maintain our proprietary position.
- We seek to protect our proprietary information, in part, using confidentiality and invention assignment agreements with our commercial partners, collaborators, employees, and consultants.
Partnerships
- August 2020, EBIR entered into a Technology Transfer Agreement with Mucokinetica to acquire its intellectual property and all assets associated with the inhaled nafamostat program.
- MPAR is being tested clinically in partnership with Quotient Sciences, using its integrated Translational Pharmaceutics® platform to search for a PF614-MPAR formulation that allows conversion into oxycodone within the prescribed dose range but reduces conversion to oxycodone at higher than prescribed dose levels in an overdose scenario. pain medications are essential for improving the care and outcomes of a majority of Americans who live with chronic pain.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LGND | Ligand Pharmaceuticals Incorpor | USD 303.53 | ▼ 1.39% |
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 89.27 | ▼ 1.79% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.09 | ▼ 0.35% |
| PRAX | Praxis Precision Medicines, Inc | USD 252.96 | ▼ 2.3% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 42.93 | ▼ 2.23% |
| AXSM | Axsome Therapeutics, Inc. | USD 145.04 | ▼ 7.07% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 24, 2026 at 13:34 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt